Effect of eicosapentaenoic acid administration on apnea hypopnea index in sleep apnea patients who underwent percutaneous coronary intervention

Effect of eicosapentaenoic acid administration on apnea hypopnea index in sleep apnea patients who underwent percutaneous coronary intervention - Effect of eicosapentaenoic acid administration on sleep apnea patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019318

Enrollment

100

Registered

2015-10-12

Start date

2015-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep apnea

Interventions

Oral eicosapentaenoic acid 1800 mg/day (900 mg x2) No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Sleep apnea patients who are diagnosed by apnea hypopnea index>5 on polysomnography after percutaneous coronary intervention, and also already diagnosed with dyslipidemia, with informed consent for inclusion.

Exclusion criteria

Exclusion criteria: (i) Patients who are already administered eicosapentaenoic acid at the time of polysomnography (ii) Patients with allergic reaction against eicosapentaenoic acid (iii) Patients with malignant neoplasm with life expectancy <6 months

Design outcomes

Primary

Measure	Time frame
Apnea hypopnea index (comparison between before and 6 months after administration)	—

Secondary

Measure	Time frame
(i) Fatty acid fraction, lipid profiles (ii) Intima-media thickness of carotid artery (iii) Cardiac functions on transthoracic echocardiography (iv) Flow-mediated dilation (FMD) (v) Neurohumoral factors (plasma renin activity, plasma aldosterone concentration, catecholamines, brain natriuretic peptide (BNP)) (vi) Systemic blood pressure, heart rate (vii) Cardiothoracic ratio (viii) Adverse cardiovascular event rate	—

Measure

Time frame

(i) Fatty acid fraction, lipid profiles (ii) Intima-media thickness of carotid artery (iii) Cardiac functions on transthoracic echocardiography (iv) Flow-mediated dilation (FMD) (v) Neurohumoral factors (plasma renin activity, plasma aldosterone concentration, catecholamines, brain natriuretic peptide (BNP)) (vi) Systemic blood pressure, heart rate (vii) Cardiothoracic ratio (viii) Adverse cardiovascular event rate

—

Countries

Japan

Contacts

Public ContactKentaro Jujo

Nishiarai Heart Center Hospital Department of Cardiology

juken1123@mac.com+81358380730

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026